Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma

Dusan Klos, Jan Hanuliak, Radka Lemstrova, Beatrice Mohelnikova-Duchonova, Jana Zapletalova, Bohuslav Melichar, Juraj Risko

. 2023 ; 124 (5) : 345-350.

Status minimální Jazyk angličtina Země Slovensko

Perzistentní odkaz   https://www.medvik.cz/link/bmc23023155

OBJECTIVES: The aim of this study is to evaluate the results of treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at a single center. METHODS: We conducted a retrospective single-center observational cohort study of consecutive patients with DMPM treated by CRS-HIPEC at the Department of Surgery I of the University Hospital in Olomouc, Czech Republic. RESULTS: Data on a total of 16 patients were processed. The study group of 16 patients had six (37.5 %) women. The mean age was approximately 62 years. Complete cytoreduction was achieved in all patients (100 %) (CC0: 75 %, CC1: 25 %). All patients underwent a closed form of HIPEC with cisplatin and doxorubicin for 90 min. The mean hospital stay was 13.5 days, including 4.38 days in the ICU (13.5 ± 5.07 and 4.38 ± 1.49, respectively). Major postoperative complications (CD grades 3–4) occurred in four patients (25 %). In-hospital mortality was 6.25 %. In the study group, the median overall survival was 20 months, and the median disease-free survival was 10.3 months. CONCLUSIONS: Also under the conditions at our specialized center, CRS-HIPEC is considered as an effective, affordable, and safe therapy with OS, DFS, morbidity, and mortality rates comparable to those reported in the literature (Tab. 5, Fig. 2, Ref. 28).

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc23023155
003      
CZ-PrNML
005      
20240109151137.0
007      
ta
008      
240109s2023 xo d f 000 0|eng||
009      
AR
024    0_
$a 10.4149/BLL_2023_052 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xo
100    1_
$a Klos, Dušan $7 xx0081738 $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
245    10
$a Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma / $c Dusan Klos, Jan Hanuliak, Radka Lemstrova, Beatrice Mohelnikova-Duchonova, Jana Zapletalova, Bohuslav Melichar, Juraj Risko
504    __
$a Literatura
520    9_
$a OBJECTIVES: The aim of this study is to evaluate the results of treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at a single center. METHODS: We conducted a retrospective single-center observational cohort study of consecutive patients with DMPM treated by CRS-HIPEC at the Department of Surgery I of the University Hospital in Olomouc, Czech Republic. RESULTS: Data on a total of 16 patients were processed. The study group of 16 patients had six (37.5 %) women. The mean age was approximately 62 years. Complete cytoreduction was achieved in all patients (100 %) (CC0: 75 %, CC1: 25 %). All patients underwent a closed form of HIPEC with cisplatin and doxorubicin for 90 min. The mean hospital stay was 13.5 days, including 4.38 days in the ICU (13.5 ± 5.07 and 4.38 ± 1.49, respectively). Major postoperative complications (CD grades 3–4) occurred in four patients (25 %). In-hospital mortality was 6.25 %. In the study group, the median overall survival was 20 months, and the median disease-free survival was 10.3 months. CONCLUSIONS: Also under the conditions at our specialized center, CRS-HIPEC is considered as an effective, affordable, and safe therapy with OS, DFS, morbidity, and mortality rates comparable to those reported in the literature (Tab. 5, Fig. 2, Ref. 28).
700    1_
$a Hanuliak, Jan $7 xx0233032 $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Lemstrová, Radmila $7 xx0233024 $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Mohelníková-Duchoňová, Beatrice $7 xx0233023 $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Zapletalová, Jana, $d 1962- $7 xx0111614 $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Riško, Juraj $7 xx0233031 $u Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
773    0_
$t Bratislavské lekárske listy $x 0006-9248 $g Roč. 124, č. 5 (2023), s. 345-350 $w MED00000845
856    41
$u http://www.elis.sk/download_file.php?product_id=7991&session_id=7cmce1hbsfsdgujb6b93572nv2 $y plný text volně přístupný
910    __
$a ABA008 $b A 4 $c 1067 $y 0 $z 0
990    __
$a 20240109132428 $b ABA008
991    __
$a 20240109151134 $b ABA008
999    __
$a min $b bmc $g 2033205 $s 1209606
BAS    __
$a 3
BMC    __
$a 2023 $b 124 $c 5 $d 345-350 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845 $n Bratisl Lek Listy
LZP    __
$a NLK 2024-02/kv

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...